CanSino Biologics Inc.
CanSino Biologics Inc. Fundamental Analysis
CanSino Biologics Inc. (CASBF) shows moderate financial fundamentals with a PE ratio of -7789.36, profit margin of -0.08%, and ROE of -0.02%. The company generates $1.6B in annual revenue with strong year-over-year growth of 26.18%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 46.7/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CASBF's fundamental strength across five key dimensions:
Efficiency Score
WeakCASBF struggles to generate sufficient returns from assets.
Valuation Score
ModerateCASBF shows balanced valuation metrics.
Growth Score
ModerateCASBF shows steady but slowing expansion.
Financial Health Score
ExcellentCASBF maintains a strong and stable balance sheet.
Profitability Score
WeakCASBF struggles to sustain strong margins.
Key Financial Metrics
Is CASBF Expensive or Cheap?
P/E Ratio
CASBF trades at -7789.36 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CASBF's PEG of 9.81 indicates potential overvaluation.
Price to Book
The market values CanSino Biologics Inc. at 1.33 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 313.66 times EBITDA. This signals the market has high growth expectations.
How Well Does CASBF Make Money?
Net Profit Margin
For every $100 in sales, CanSino Biologics Inc. keeps $-0.08 as profit after all expenses.
Operating Margin
Core operations generate -6.44 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.02 in profit for every $100 of shareholder equity.
ROA
CanSino Biologics Inc. generates $-0.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CanSino Biologics Inc. generates limited operating cash flow of $100.86M, signaling weaker underlying cash strength.
Free Cash Flow
CanSino Biologics Inc. generates weak or negative free cash flow of $-194.24M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.56 in free cash annually.
FCF Yield
CASBF converts -1.49% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-7789.36
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
9.81
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.33
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.27
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.24
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.11
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.00
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How CASBF Stacks Against Its Sector Peers
| Metric | CASBF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -7789.36 | 29.88 | Better (Cheaper) |
| ROE | -0.02% | 682.00% | Weak |
| Net Margin | -0.08% | -46037.00% (disorted) | Weak |
| Debt/Equity | 0.24 | 0.42 | Strong (Low Leverage) |
| Current Ratio | 4.11 | 4.49 | Strong Liquidity |
| ROA | -0.01% | -16420.00% (disorted) | Weak |
CASBF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CanSino Biologics Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
3804.70%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
106.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
126.36%
Industry Style: Defensive, Growth, Innovation
High Growth